Skip to main content

Radiation-induced Xerostomia

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Martin Pharmaceuticals
1 program
1
Hyperbaric oxygenPhase 21 trial
Active Trials
NCT00682747Terminated13Est. Mar 2011
MeiraGTx
MeiraGTxNEW YORK, NY
1 program
Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced XerostomiaN/A1 trial
Active Trials
NCT05060341Active Not Recruiting22Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Martin PharmaceuticalsHyperbaric oxygen
MeiraGTxLong-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

Clinical Trials (2)

Total enrollment: 35 patients across 2 trials

Hyperbaric Oxygen for the Treatment of a Dry Mouth Which Occurred After Radiotherapy

Start: May 2008Est. completion: Mar 201113 patients
Phase 2Terminated
NCT05060341MeiraGTxLong-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

Start: Nov 2020Est. completion: Mar 202722 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.